Griseofulvin Tablets
Form: Tablets
Strength: 125 mg, 250 mg, 500 mg
Reference Brands: Grifulvin V(US); Griséofulvine(EU)
Category: Anti-fungal
Griseofulvin tablets are approved in the EU and US for treating dermatophyte skin infections. In the EU, generic formulations are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on comprehensive clinical data, with both branded and generic versions available. Both regions require detailed dossiers for approval and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We help facilitate smooth market access for griseofulvin tablets, ensuring adherence to European and American standards for effective treatment of dermatophyte infections.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Nystatin Oral Suspensions/Tablets
Strength: Tab: 500,000 units, 1,000,000 units; Sus: 100,000 units/mL, 500,000 units/5 mL
Form: Tablets/Suspensions
Reference Brands: Mycostatin, Nilstat, Nystop(US)
View Details
Nystatin Topical Creams And Ointments
Strength: 100,000 units/g, 100,000–300,000 units/g
Form: Topical Creams and Ointments
Reference Brands: Mycostatin, Nilstat, Nystop(US)
View Details
Micafungin Intravenous (Iv) Powder
Strength: 50 mg, 100 mg/vial
Form: Intravenous (IV) Powder
Reference Brands: Mycamine(US & EU)
View Details
Anidulafungin Injection
Strength: 50 mg/vial
Form: Intravenous (IV) Powder
Reference Brands: Eraxis(US)
View Details